Tegafur-uracil
- Generic Name
- Tegafur-uracil
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H13FN4O5
- CAS Number
- 74578-38-4
- Unique Ingredient Identifier
- HMI5GR78FR
- Background
Tegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd. It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.
- Indication
Tegafur-uracil is indicated for the first line treatment of metastatic colorectal cancer with concomitant administration of calcium folinate. Colorectal cancer is the third most diagnosed cancer and 30% of the cases can present the metastatic state.
- Associated Conditions
- -
- Associated Therapies
- -
S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer
- Conditions
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Yokohama City University
- Target Recruit Count
- 500
- Registration Number
- NCT00336947
- Locations
- ๐ฏ๐ต
National Hospital Organization - Himeji Medical Center, Himeji-shi, Hyogo, Japan
๐ฏ๐ตFujita Health University, Toyoake, Aichi, Japan
๐ฏ๐ตMie University Graduate School of Medicine, Tsu, Mie, Japan
Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-05-26
- Lead Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Target Recruit Count
- 340
- Registration Number
- NCT00209742
- Locations
- ๐ฏ๐ต
ใป Hokkaido University Hospital (Hokkaido University Graduate School of Medicine / School of Medicine), Sapporo, Hokkaido, Japan
Study Evaluating Isovorin in Colon Cancer
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-08-13
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 650
- Registration Number
- NCT00195585
Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors
- Conditions
- First Posted Date
- 2004-04-21
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT00009828
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-04-20
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT00009815
Fluorouracil-Uracil and Leucovorin in Treating Women With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-04-19
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00005608
- Locations
- ๐บ๐ธ
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2004-04-12
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00004860
- Locations
- ๐บ๐ธ
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
๐บ๐ธJohns Hopkins Oncology Center, Baltimore, Maryland, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Combination Chemotherapy and Radiation Therapy in Treating Patients With Colorectal Cancer
- Conditions
- First Posted Date
- 2004-02-06
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00002801
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy In Treating Patients With Advanced Cancer
- Conditions
- First Posted Date
- 2003-05-02
- Last Posted Date
- 2013-04-08
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 36
- Registration Number
- NCT00003925
- Locations
- ๐บ๐ธ
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.